OncoDaily brought together sarcoma experts, clinicians, researchers, industry leaders, and oncology professionals during the ASCO 2026 Annual Meeting in Chicago for a focused live program dedicated to one of the most complex fields in oncology: sarcoma care.
Held on Friday, May 29, 2026, at Hilton Chicago, OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition created a dedicated space for discussion around the science, strategy, and clinical questions shaping the next era of sarcoma treatment. The program was designed as more than a meeting session. It was an expert-led gathering focused on rare cancers, emerging evidence, and the future of precision oncology.
The event was supported by Eli Lilly and Company as Foundational Partner and US WorldMeds as Bronze Sponsor.
Sarcoma remains a rare and heterogeneous group of cancers, but its clinical challenges are urgent and global. Diagnosis, molecular classification, access to expert care, trial development, and treatment sequencing continue to require close collaboration across specialties and borders. Against this background, OncoDaily’s Sarcoma Edition offered a timely platform for dialogue at one of the world’s most important oncology meetings.
A Focused Program Led By International Sarcoma Experts
The evening was co-chaired by Dr. Sandra D’Angelo and Dr. Herbert Loong, two leaders with strong clinical and research experience in sarcoma, early drug development, immunotherapy, and innovative treatment strategies.
Dr. Sandra D’Angelo, medical oncologist at Memorial Sloan Kettering Cancer Center, has focused her work on advancing immunotherapy approaches for sarcoma, including biomarker-driven strategies and adoptive T-cell therapies. Her translational research program continues to explore how immune-based treatments can be better understood and applied in these rare tumors.
Dr. Herbert Loong, Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong and Medical Director of the Phase 1 Clinical Trial Centre, brought broad experience in thoracic oncology, sarcoma, and early-phase clinical trials. His work in experimental therapeutics and global oncology collaboration added an important international perspective to the discussion.
Together, the co-chairs guided an evening centered on scientific progress, clinical uncertainty, and the practical questions facing the sarcoma community.
From Biomarkers To Novel Therapeutics
The program opened with networking, followed by expert presentations covering several major areas of sarcoma research and treatment.
Dr. Robin Jones, medical oncologist and Head of the Sarcoma Unit at The Royal Marsden, delivered a talk on targeted therapies and biomarker testing for diagnosis and treatment. His presentation reflected the growing importance of molecular classification in sarcoma care, where accurate diagnosis and biomarker-informed decisions increasingly influence therapeutic planning.
Dr. Javier Martín-Broto, founder member of the Spanish Group for Research on Sarcomas and leader of the Sarcoma Latin-American & European Sarcoma Network consortium, discussed the role of combining chemotherapy with immuno-oncology agents. His session addressed one of the central questions in modern sarcoma treatment: how to build rational combinations that can improve outcomes while respecting the biological diversity of these diseases.
Dr. D’Angelo then presented on T-cell receptor therapy, an area of growing interest in selected sarcoma subtypes. Her talk highlighted the promise of cellular therapy approaches while also reflecting the complexity of translating these strategies into broader clinical practice.
Dr. Loong concluded the lecture portion with a presentation on antibody-drug conjugates and novel therapeutics, focusing on therapeutic platforms that are gaining attention across oncology and may play an expanding role in sarcoma research.
Turning Expert Knowledge Into Dialogue
Following the presentations, the program moved into an interactive Q&A with the co-chairs and speakers. This format allowed the discussion to extend beyond individual lectures and into broader clinical and research questions.
The exchange reflected the real-world complexity of sarcoma care. Unlike more common cancers, sarcomas often require highly specialized expertise, careful pathological and molecular evaluation, and strong referral networks. New treatment approaches are emerging, but their integration into practice depends on evidence generation, trial design, patient selection, and collaboration between academic centers, cooperative groups, and industry partners.
The Grand Rounds format created room for these issues to be discussed directly among experts and attendees, making the event both educational and practical.
A Rare Cancer Field With Global Relevance
Although sarcoma is rare, the lessons from sarcoma research extend far beyond one disease group. The field sits at the intersection of precision diagnostics, molecularly defined treatment, immunotherapy, cellular therapy, and early-phase drug development. It also reflects broader challenges in oncology, including how to design trials for rare tumors, how to bring new therapies to small patient populations, and how to ensure expert care is accessible across different health systems.
By placing sarcoma at the center of a dedicated ASCO 2026 program, OncoDaily highlighted the importance of rare cancer conversations within the global oncology agenda.
The evening also emphasized the value of bringing together different voices: clinicians treating patients, researchers designing trials, leaders advancing new therapeutic platforms, and oncology professionals working to translate scientific progress into better care.
Supported By Partners Committed To Oncology Progress
The event was supported by Eli Lilly and Company as Foundational Partner and US WorldMeds as Bronze Sponsor. Their support helped make possible a focused educational and networking program dedicated to advancing discussion in sarcoma care.
OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition reflected OncoDaily’s broader commitment to creating meaningful spaces for oncology professionals to exchange knowledge, discuss emerging science, and connect around areas of high clinical need.
A Strong Step Forward For Sarcoma Conversations At ASCO
The Sarcoma Edition closed with networking, allowing attendees to continue the conversation beyond the formal session. For a rare cancer field where collaboration is essential, this final part of the evening carried particular value.
The program brought together leading experts, timely topics, and a focused audience around a shared goal: understanding where sarcoma care is moving and how the oncology community can help shape what comes next.
OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition was not only an expert session. It was a reminder that rare cancers deserve dedicated attention, strong scientific dialogue, and global collaboration.